Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2019

Open Access 01-12-2019 | Computed Tomography | Case report

Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report

Authors: Shusei Sano, Shinji Nakata, Shuichi Wada, Masatsugu Kuroiwa, Hiroki Sakai, Kei Kusama, Taiichi Machida, Akihito Nishio, Ichiro Ito, Harutsugu Sodeyama

Published in: World Journal of Surgical Oncology | Issue 1/2019

Login to get access

Abstract

Background

Advanced hepatocellular carcinoma (HCC) with macrovascular invasion has an extremely dismal prognosis. We report a rare case of multiple HCC with tumor thrombosis in the portal vein and inferior vena cava that was initially treated with hepatic arterial infusion chemotherapy (HAIC); later resection revealed pathological complete response.

Case presentation

A 75-year-old man presented with HCC in his right liver, with tumor thrombosis growing to the right portal vein and the inferior vena cava, and bilateral intrahepatic liver metastases. He underwent HAIC (5-fluorouracil [170 mg/m2] + cisplatin [7 mg/m2]) via an indwelling port. Although the tumor shrank and tumor marker levels decreased rapidly, we abandoned HAIC after one cycle because of cytopenia. We resumed HAIC 18 months later because of tumor progression, using biweekly 5-fluorouracil only [1000 mg] due to renal dysfunction. However, after 54 months, the HAIC indwelling port was occluded. The patient therefore underwent a right hepatectomy to resect the residual lesion. Histopathological findings showed complete necrosis with no viable tumor cells. The patient has been doing well without postoperative adjuvant therapy for more than 10 years after initially introducing HAIC and 6 years after the resection, without evidence of tumor recurrence.

Conclusions

HAIC can be an effective alternative treatment for advanced HCC with macrovascular invasion.
Literature
1.
go back to reference Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–7.CrossRef Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–7.CrossRef
2.
go back to reference Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013;109(7):1904–7.CrossRef Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013;109(7):1904–7.CrossRef
3.
go back to reference EASL. Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRef EASL. Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRef
4.
go back to reference Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.CrossRef Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.CrossRef
5.
go back to reference Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.CrossRef Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.CrossRef
6.
go back to reference Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRef Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRef
7.
go back to reference Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.CrossRef Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.CrossRef
8.
go back to reference Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.CrossRef Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.CrossRef
9.
go back to reference Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, et al. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. J Clin Oncol. 2011;29(12):e330–2.CrossRef Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, et al. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. J Clin Oncol. 2011;29(12):e330–2.CrossRef
10.
go back to reference Kermiche-Rahali S, Di Fiore A, Drieux F, Di Fiore F, Francois A, Scotte M. Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. World J Surg Oncol. 2013;11(1):171.CrossRef Kermiche-Rahali S, Di Fiore A, Drieux F, Di Fiore F, Francois A, Scotte M. Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. World J Surg Oncol. 2013;11(1):171.CrossRef
11.
go back to reference Takano M, Kokudo T, Miyazaki Y, Kageyama Y, Takahashi A, Amikura K, et al. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. World J Gastroenterol. 2016;22(42):9445–50.CrossRef Takano M, Kokudo T, Miyazaki Y, Kageyama Y, Takahashi A, Amikura K, et al. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. World J Gastroenterol. 2016;22(42):9445–50.CrossRef
12.
go back to reference Kim DH, Cho E, Cho SB, Choi SK, Kim S, Yu J, et al. Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): a case report and literature review. Medicine (Baltimore). 2018;97(42):e12866.CrossRef Kim DH, Cho E, Cho SB, Choi SK, Kim S, Yu J, et al. Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): a case report and literature review. Medicine (Baltimore). 2018;97(42):e12866.CrossRef
13.
go back to reference Shinoda M, Kishida N, Itano O, Ei S, Ueno A, Kitago M, et al. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature. World J Surg Oncol. 2015;13:144.CrossRef Shinoda M, Kishida N, Itano O, Ei S, Ueno A, Kitago M, et al. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature. World J Surg Oncol. 2015;13:144.CrossRef
14.
go back to reference Park JG, Park SY, Lee HW. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy. World J Gastroenterol. 2015;21(8):2568–72.CrossRef Park JG, Park SY, Lee HW. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy. World J Gastroenterol. 2015;21(8):2568–72.CrossRef
15.
go back to reference Kitajima T, Hatano E, Mitsunori Y, Taura K, Fujimoto Y, Mizumoto M, et al. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. Clin J Gastroenterol. 2015;8(5):300–5.CrossRef Kitajima T, Hatano E, Mitsunori Y, Taura K, Fujimoto Y, Mizumoto M, et al. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. Clin J Gastroenterol. 2015;8(5):300–5.CrossRef
16.
go back to reference Katafuchi E, Takami Y, Wada Y, Tateishi M, Ryu T, Mikagi K, et al. Long-term maintenance of complete response after sorafenib treatment for multiple lung metastases from hepatocellular carcinoma. Case Rep Gastroenterol. 2015;9(2):285–90.CrossRef Katafuchi E, Takami Y, Wada Y, Tateishi M, Ryu T, Mikagi K, et al. Long-term maintenance of complete response after sorafenib treatment for multiple lung metastases from hepatocellular carcinoma. Case Rep Gastroenterol. 2015;9(2):285–90.CrossRef
17.
go back to reference Oh YJ, Park YM, Kim BH, Kim MJ, Cho JH, Cha CW, et al. A case of hepatocellular carcinoma with pulmonary metastases treated successfully with a combination of repeated hepatic arterial infusion epirubicin and cisplatin chemotherapy and systemic low-dose infusion of 5-fluorouracil. Gut and liver. 2009;3(4):343–8.CrossRef Oh YJ, Park YM, Kim BH, Kim MJ, Cho JH, Cha CW, et al. A case of hepatocellular carcinoma with pulmonary metastases treated successfully with a combination of repeated hepatic arterial infusion epirubicin and cisplatin chemotherapy and systemic low-dose infusion of 5-fluorouracil. Gut and liver. 2009;3(4):343–8.CrossRef
18.
go back to reference Kurahashi S, Sano T, Natsume S, Senda Y, Yamaura H, Inaba Y, et al. Surgical treatment after hepatic arterial infusion chemotherapy for hepatocellular carcinoma extending into the right atrium. Surgical case reports. 2015;1(1):47.CrossRef Kurahashi S, Sano T, Natsume S, Senda Y, Yamaura H, Inaba Y, et al. Surgical treatment after hepatic arterial infusion chemotherapy for hepatocellular carcinoma extending into the right atrium. Surgical case reports. 2015;1(1):47.CrossRef
19.
go back to reference Kogure T, Iwasaki T, Ueno Y, Kanno N, Fukushima K, Yamagiwa Y, et al. Complete remission of a case of hepatocellular carcinoma with tumor invasion in inferior vena cava and with pulmonary metastasis successfully treated with repeated arterial infusion chemotherapy. Hepatogastroenterology. 2007;54(79):2113–6.PubMed Kogure T, Iwasaki T, Ueno Y, Kanno N, Fukushima K, Yamagiwa Y, et al. Complete remission of a case of hepatocellular carcinoma with tumor invasion in inferior vena cava and with pulmonary metastasis successfully treated with repeated arterial infusion chemotherapy. Hepatogastroenterology. 2007;54(79):2113–6.PubMed
20.
go back to reference Kim YG, Eun JR, Kim TN, Lee HJ, Kim JW, Chang JC, et al. Pathological complete remission of advanced hepatocellular carcinoma with main portal vein tumor thrombosis by hepatic arterial infusion chemotherapy. Gut and liver. 2010;4(2):266–9.CrossRef Kim YG, Eun JR, Kim TN, Lee HJ, Kim JW, Chang JC, et al. Pathological complete remission of advanced hepatocellular carcinoma with main portal vein tumor thrombosis by hepatic arterial infusion chemotherapy. Gut and liver. 2010;4(2):266–9.CrossRef
21.
go back to reference Lin CC, Hung CF, Chen WT, Lin SM. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: impact of early response to 4 weeks of treatment. Liver cancer. 2015;4(4):228–40.CrossRef Lin CC, Hung CF, Chen WT, Lin SM. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: impact of early response to 4 weeks of treatment. Liver cancer. 2015;4(4):228–40.CrossRef
22.
go back to reference Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2003;9(12):2666–70.CrossRef Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2003;9(12):2666–70.CrossRef
23.
go back to reference Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588–95.CrossRef Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588–95.CrossRef
24.
go back to reference Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Yamaguchi K, et al. Sorafenib versus hepatic arterial infusion chemotherapy as initial treatment for hepatocellular carcinoma with advanced portal vein tumor thrombosis. Liver cancer. 2017;6(4):275–86.CrossRef Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Yamaguchi K, et al. Sorafenib versus hepatic arterial infusion chemotherapy as initial treatment for hepatocellular carcinoma with advanced portal vein tumor thrombosis. Liver cancer. 2017;6(4):275–86.CrossRef
25.
go back to reference Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, et al. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: a prospective cohort study. Molecular and clinical oncology. 2017;7(6):1013–20.PubMedPubMedCentral Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, et al. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: a prospective cohort study. Molecular and clinical oncology. 2017;7(6):1013–20.PubMedPubMedCentral
26.
go back to reference Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. The Lancet Gastroenterology & hepatology. 2018;3(6):424–32.CrossRef Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. The Lancet Gastroenterology & hepatology. 2018;3(6):424–32.CrossRef
27.
go back to reference Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, et al. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol. 2012;47(6):686–95.CrossRef Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, et al. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol. 2012;47(6):686–95.CrossRef
28.
go back to reference Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat. 2009;12(3):74–80.CrossRef Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat. 2009;12(3):74–80.CrossRef
29.
go back to reference Sakamaki A, Kamimura K, Abe S, Tsuchiya A, Takamura M, Kawai H, et al. Spontaneous regression of hepatocellular carcinoma: a mini-review. World J Gastroenterol. 2017;23(21):3797–804.CrossRef Sakamaki A, Kamimura K, Abe S, Tsuchiya A, Takamura M, Kawai H, et al. Spontaneous regression of hepatocellular carcinoma: a mini-review. World J Gastroenterol. 2017;23(21):3797–804.CrossRef
Metadata
Title
Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report
Authors
Shusei Sano
Shinji Nakata
Shuichi Wada
Masatsugu Kuroiwa
Hiroki Sakai
Kei Kusama
Taiichi Machida
Akihito Nishio
Ichiro Ito
Harutsugu Sodeyama
Publication date
01-12-2019

Other articles of this Issue 1/2019

World Journal of Surgical Oncology 1/2019 Go to the issue